Unit
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
SAKK 01/18 Reduced intensity radio-chemotherapy for satge IIA/B seminoma. A multicenter, open label phase II trial with 2 cohorts
Jul 24, 2019Main objective: To investigate efficacy of a stage-adapted tratment regimen in stage IIA/B seminoma based on the preliminary experience gained in SAKK 01/10. The Goal is to further safely de-escalate Treatment while maintaining / enhancing efficacy.
Clinical Studies - Jul 24, 2019 - Jul 24, 2030
Ongoing
Project leader: Putora Paul Martin
Members: Plasswilm Ludwig, Rothermundt Christian, Patzl Sigrid, Fischer Stefanie
SAKK 21/18 Ribociclib-endocrine combination therapy versus chemotherapy as 1st line treatment in patients with visceral metastatic breast cancer. A mul-ticenter, randomized phase III trial
Jun 25, 2019Breast cancer is the most frequent malignancy in women and the leading cause of cancer mortality in most countries in Europe. Metastatic breast cancer remains an incurable disease with a median overall survival (OS) of 2–4 years and a 5 year surviv...
Clinical Studies - Jun 25, 2019 - Dec 31, 2026
Ongoing
Project leader: Hasler-Strub Ursula
A multicentre randomised phase III trial comparing atezolizumab
Jun 20, 2019Evaluation einer Immuntherapie in der ersten Therapielinie in Kombination mit einer Standard Chemo-/Avastintherapie bei Patienten mit malignem Mesotheliom
Clinical Studies - Jun 20, 2019 - Jul 4, 2025
Ongoing
Project leader: Früh Martin
Open label, non-randomized, Phase IB study to characterize safety, tolerability and recommended dose of EDO-S101, a first-in-class alkylating histone deacetylase inhibition (HDACi) fusion molecule, in combination with Nivolumab in patients with refractory, locally advanced or metastatic melanoma
May 2, 2019Neuere Immuntherapien zur Behandlung des fortgeschrit-tenen, metastasierten Melanoms haben zu einer Verbes-serung des Gesamtüberlebens geführt. Diese Immuntherapien führen zu einer Verstärkung der natürlichen Krebsabwehr durch das Immunsystem. Einige...
Clinical Studies - May 2, 2019 - Dec 17, 2023
Automatically Closed
Project leader: Jörger Markus
Open label, non-randomized, Phase IB study to characterize safety, tolerability and recommended dose of EDO-S101, a first-in-class alkylating histone deacetylase inhibition (HDACi) fusion molecule, in combination with Nivolumab in patients with refractory, locally advanced or metastatic melanoma
May 2, 2019Neuere Immuntherapien zur Behandlung des fortgeschrit-tenen, metastasierten Melanoms haben zu einer Verbesse-rung des Gesamtüberlebens geführt. Diese Immuntherapien führen zu einer Verstärkung der natürlichen Krebsabwehr durch das Immunsystem. Einige...
Clinical Studies - May 2, 2019 - Aug 30, 2023
Automatically Closed
Project leader: Jörger Markus
ENIGMA: Open label, non-randomized, Phase IB study to character-ize safety, tolerability and recommended dose of EDO-S101, a first-in-class alkylating histone deacetylase inhibition (HDACi) fusion molecule, in combination with Nivolumab in patients with refractory, locally advanced or metastatic melanoma
May 2, 2019Neuere Immuntherapien zur Behandlung des fortgeschrit-tenen, metastasierten Melanoms haben zu einer Verbesse-rung des Gesamtüberlebens geführt. Diese Immuntherapien führen zu einer Verstärkung der natürlichen Krebsabwehr durch das Immunsystem. Einig...
Clinical Studies - May 2, 2019 - Dec 31, 2024
Ongoing
Project leader: Jörger Markus
Members: Wittwer Yvonne, Quinter Janine
Peace-4
Apr 26, 2019Prostate cancer is the most frequent cancer in Western countries and castrate- resistant prostate cancer (CRPC) is its lethal form. Survival for CRPC patients with metastases now encompasses 30 months, while that for patients without metastases is ab...
Clinical Studies - Apr 26, 2019 - May 6, 2027
Ongoing
Project leader: Omlin Aurelius
A Phase 3 Study Comparing Daratumumab, VELCADE (borte-zomib), Lenalidomide, and Dexamethasone (D-VRD) vs VELCADE, Lenalidomide, and Dexamethasone (VRD) in Sub-jects with Previously Untreated Multiple Myeloma who are Eligi-ble for High-dose Therapy
Apr 18, 2019This is a randomized, open-label, multicenter study evalu-ating subjects with newly diagnosed multiple myeloma who are deemed eligible for high-dose therapy. Approximately 690 subjects will be stratified by International Staging Sys-tem (ISS) Stage I...
Clinical Studies - Apr 18, 2019 - Dec 1, 2029
Ongoing
Project leader: Silzle Tobias
Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers
Apr 15, 2019Kombination von Nivolumab mit dem anti-IL8 monoklona-len Antikörper BMS-986253 in PatientInnen mit selektierten fortgeschrittenen soliden Malignomen und erhöhten IL-8 Blutspiegeln.
Clinical Studies - Apr 15, 2019 - Dec 31, 2020
Automatically Closed
Project leader: Jörger Markus
A phase III trial of marizomib in combination with standard
Jan 14, 2019Phase 1/2 Open-label Trial of Tinostamustine Conditioning and Autologous Stem Cell Transplantation for Salvage Treatment in Relapsed / Refractory Multiple Myeloma (TITANIUM 1)
Clinical Studies - Jan 14, 2019 - Jun 20, 2019
Automatically Closed
Project leader: Hess Dagmar
The „seed and soil“-based pathogenesis of proteasome inhibitor resistance in multiple myeloma
Jan 1, 2019Using the novel method of single-sell RNA sequencing, recently established by the Institute of Immunobiology at MFZ, KSSG, and our experience and knowledge about proteasome inhibitor resistance of myeloma plasma cells in vitro, we shall use the MFZ s...
Fundamental Research - Jan 1, 2019 - Dec 31, 2019
Automatically Closed
Project leader: Besse Lenka
Members: Besse Andrej, Schwestermann Jonas
Prospective Observational international Registry of Patients with newly diagnosed peripheral T-Cell Lymphoma
Jan 1, 2019
Clinical Studies - Jan 1, 2019 - Dec 31, 2030
Ongoing
Project leader: Hitz Felicitas
Members: Demmer-Steingruber Ruth, Müller Fiona
A phase III trial of marizomib in combination with standard
Dec 13, 2018Marizomib in Glioblastoma
Clinical Studies - Dec 13, 2018 - Nov 13, 2021
Automatically Closed
Project leader: Hundsberger Thomas
MK-3475-495 KeyImPaCT
Dec 12, 2018Open-label randomisierte Phase II Studie, welche in der Erstlinientherapie bei Patienten mit metastasiertem NSCLC die Kombination von Pembrolizumab mit entweder MK-4280 oder lenvatinib untersucht. Ausgenommen sind Patienten für die eine zielgericht...
Clinical Studies - Dec 12, 2018 - Dec 19, 2020
Automatically Closed
Project leader: Schmid Sabine
IBCSG 55-17 “Touch” Phase II open-label, multicenter, randomized trial of neo-adjuvant palbociclib in combination with hormonal therapy and HER2 blockade versus paclitaxel in combination with HER2 blockade for elderly patients with hormone receptor positive/HER2 positive early breast cancer
Dec 4, 2018CDK4/6-Inhibitoren bringen enorme Verbesserungen bei der Behandlung von Patienten mit fortgeschrittenen, HR+ (Hormonrezeptor positiv)/HER2- (human epidermal growth factor receptor 2 negativ) BC (Brustkrebserkrankungen). Palbociclib und andere CDK4/6-...
Clinical Studies - Dec 4, 2018 - Dec 31, 2021
Automatically Closed
Project leader: Weder Patrik
TLD-1, a novel Liposomal Doxorubicin, in Patients with Advanced Solid Tumors; a multicenter open-label single-arm phase I trial.
Oct 26, 2018In dieser Studie wird zum ersten Mal die Sicherheit und Wirksamkeit eines neuen Medikaments (Talidox) bei Menschen untersucht. Bei dem neuen Medikament handelt es sich um einen bekannten Wirkstoff, das Chemotherapeutikum Doxorubicin, welches in einer...
Clinical Studies - Oct 26, 2018 - Dec 31, 2026
Ongoing
Project leader: Hess Dagmar
Members: Harder Anja, Quinter Janine
Trial SAKK 19/17: First line durvalumab in patients with PD-L1 positve, advanced NSCLC with performance status 2 unsuitable for combination chemotherapy. A multicenter, single-arm phase II trial
Oct 23, 2018Lung cancer is the leading cause of cancer deaths. An estimated 30 to 40% of patients diagnosed with NSCLC have a poor PS defined as a score of 2 or higher on the ECOG scale. PS 2 patients are often underrepresented in clinical trials despite represe...
Clinical Studies - Oct 23, 2018 - Nov 23, 2021
Automatically Closed
Project leader: Früh Martin
SAKK 57/16. NAPAGE NAb-PAclitaxel and GEmcita-bine in advanced soft tissue sarcoma. A multicenter open-label single arm phase Ib/IIa trial
Oct 2, 2018Multizentrische Phase Ib/IIa Studie für Patientinnen und Patienten mit metastasiertem Weichteilsarkom, welche bereits eine oder zwei palliative Chemothera-pien erhalten haben. Zunächst erfolgt eine Dosisfin-dung mit Nab-Paclitaxel and Gemcitabine un...
Clinical Studies - Oct 2, 2018 - Oct 9, 2021
Automatically Closed
Project leader: Rothermundt Christian
Identifying and targeting the “Achilles’ heel” in proteasome inhibitor-resistant multiple myeloma
Oct 1, 2018The proposal aims at understanding the biology of proteasome inhibitor (PI)-refractory multiple myeloma (MM), in particular the specific vulnerabilities of PI-refractory MM, or so called “Achilles’ heel”, towards development of novel treatment option...
Fundamental Research - Oct 1, 2018 - Dec 31, 2021
Automatically Closed
Project leader: Driessen Christoph
Members: Besse Andrej, Kraus Marianne, Besse Lenka, Mendez Lopez Max
Randomisierte klinische Studie zum Vergleich der Vollständigkeit der adjuvanten Chemotherapie nach früher vs. später Stomarückverlagerung bei Patienten mit Rektumkarzinom nach tiefer anteriorer Resektion
Sep 24, 2018Ziel der CoCStom-Studie ist es, den optimalen Zeitpunkt der Rückverlagerung eines künstlichen Darmausgangs (Stoma) zu ermitteln, der im Rahmen der chirurgischen Entfernung des Mastdarms beim lokal fortgeschrittenen Enddarmkrebs (Rektumkarzinom) vorüb...
Clinical Studies - Sep 24, 2018 - Nov 30, 2020
Completed
Project leader: Marti Lukas, Kienle P, Hofheinz R
Members: Beutner Ulrich, Gueller Ulrich, Brunner Walter, Bischofberger Stephan